What is Rapid Micro Biosystems's market cap?

Rapid Micro Biosystems (RPID) has a market capitalization of $86.7M and trades on NASDAQ.

What is Rapid Micro Biosystems's revenue and profitability?

Rapid Micro Biosystems generated $34.4M in trailing twelve-month revenue with a net loss of $50.1M, representing a net margin of -145.8%, with free cash flow of -$38.0M. These figures are based on the Q1 2026 filing.

Who are Rapid Micro Biosystems's competitors?

Rapid Micro Biosystems's key competitors include Charles River Laboratories, Bio-Rad Laboratories, Inc.Class A, Pacific Biosciences of California, Inc., and others. These companies compete in similar markets and product categories.

Where is Rapid Micro Biosystems headquartered?

Rapid Micro Biosystems is headquartered in United States of America and employs approximately 193 people. It has been publicly traded since 2021.

Rapid Micro Biosystems

RPID

Rapid Micro Biosystems provides a proprietary automated microbial quality control platform designed to modernize the testing of pharmaceutical and biotechnology products.

Market cap

$86.69M-41.3%

Revenue$34.4M+16.0%

Net income-$50.1M-11.8%

Free cash flow-$38.0M+2.1%

EPS (diluted)-$1.11-7.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$8.0MBeat by $402.0K EPS-$0.31Miss by $0.06

Read the full report

Next report

Aug 11, 2026 (in a month)

Revenue estimate$7.9M

EPS estimate-$0.26

Financials

Q1 2026

Income statement

See full

Revenue$8.0M+11.1%

Gross profit$371.0K-8.2%

Operating income-$13.9M-18.8%

Net income-$14.3M-26.7%

EPS (diluted)-$0.31-19.2%

Balance sheet

See full

Cash & equivalents$14.1M-26.8%

Total debt$23.8M+301%

Total equity$20.4M-68.9%

Total assets$62.4M-27.0%

Cash flow

See full

Operating cash flow-$15.1M-66.1%

CapEx$394.0K+23.5%

Free cash flow-$15.5M-64.7%

Valuation & ratios

Valuation

See full

Market cap$86.69M-41.3%

Enterprise value$96.35M-31.2%

P/S2.5×-2.5×

Profitability

See full

Operating margin-144.2%-12.7pp

Net margin-145.8%-5.0pp

FCF margin-110.5%-14.9pp

Returns & leverage

See full

Return on equity-116.7%-620pp

Debt / equity1.2×+1.1×

Current ratio2.6×-2.0×

Segments

By product

See full

Service$2.4M-21.9%

Competitors

By market cap

West Pharmaceutical Services$25.3B+58.8%

Charles River Laboratories$11.3B+48.9%

Bio-Rad Laboratories$8.0B+18.3%

iRadimed$1.3B+67.0%

Ginkgo Bioworks$635.6M-4.3%

Pacific Biosciences of California$500.1M+13.4%

MacroGenics$290.5M+239%

Rapid Micro Biosystems$86.7M-43.3%

By revenue growth

Rapid Micro Biosystems+16.0%

iRadimed+14.8%

West Pharmaceutical Services+11.2%

Pacific Biosciences of California+5.0%

Bio-Rad Laboratories+1.9%

Charles River Laboratories+0.1%

Ginkgo Bioworks-37.8%

By net margin

iRadimed27.36%+1.0pp

West Pharmaceutical Services16.85%+0.7pp

Bio-Rad Laboratories6.52%+91.7pp

Charles River Laboratories-4.59%-11.1pp

Pacific Biosciences of California-80.34%+353pp

Rapid Micro Biosystems-145.81%+5.4pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

Rapid Micro Biosystems provides a proprietary automated microbial quality control platform designed to modernize the testing of pharmaceutical and biotechnology products. The company's core value proposition centers on replacing manual, error-prone testing methods with high-throughput, automated systems that accelerate manufacturing timelines and ensure data integrity. Their technology is widely adopted by leading global pharmaceutical companies and manufacturers of advanced cell and gene therapies.

Competitive position

The company is a leader in automated microbial quality control, serving 75% of the top 20 largest pharmaceutical companies and a majority of approved CAR-T therapy manufacturers.

GeographiesGlobal, United States

Customer segmentsTop 20 pharmaceutical companies, CAR-T cell therapy manufacturers, Global drug manufacturers

Business modelRazor-and-blade, Hardware-as-a-Service, Subscription services, B2B

SuppliersRaw material suppliers, Contract manufacturers, Electronic component providers, Software developers

CustomersPharmaceutical manufacturers, Biotechnology firms, Cell and gene therapy developers, Quality control laboratories

CountryUnited States of America

Listed2021

Employees193.0

CEORobert G. Spignesi Jr.

SectorHealthcare

IndustryMedical - Devices

Websiterapidmicrobio.com

FilingsSEC EDGAR

Ask your AI about Rapid Micro Biosystems.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapid Micro Biosystems's market cap?: Rapid Micro Biosystems (RPID) has a market capitalization of $86.7M and trades on NASDAQ.
What is Rapid Micro Biosystems's revenue and profitability?: Rapid Micro Biosystems generated $34.4M in trailing twelve-month revenue with a net loss of $50.1M, representing a net margin of -145.8%, with free cash flow of -$38.0M. These figures are based on the Q1 2026 filing.
Who are Rapid Micro Biosystems's competitors?: Rapid Micro Biosystems's key competitors include Charles River Laboratories, Bio-Rad Laboratories, Inc.Class A, Pacific Biosciences of California, Inc., and others. These companies compete in similar markets and product categories.
Where is Rapid Micro Biosystems headquartered?: Rapid Micro Biosystems is headquartered in United States of America and employs approximately 193 people. It has been publicly traded since 2021.